Oncosem Secures 273 Million TL 5-Year Chemotherapy Supply Deal with Cam & Sakura City Hospital

Oncosem has marked a new era in Turkey's oncology services by signing a 60‑month 273 million TL agreement with Başakşehir Cam and Sakura City Hospital.

Strategic Alliance: Expanding Oncosem's Oncology Portfolio

The deal positions Oncosem as a direct supplier within a clinical setting, elevating the hospital to a critical node in the chemotherapy treatment chain. The company will deploy the infrastructure and expert staff needed to support the hospital's average 1,200 chemotherapy sessions per year.

Financial Impact: Cash Flow and Margin Implications

■Total contract value: 273 million TL, translating to an average annual revenue stream of 45.5 million TL.

■Gross margin: Oncosem's current ~22% gross margin could climb to ~28% thanks to high‑value drug‑preparation services.

■Cash conversion cycle: A 60‑month term strengthens short‑term liquidity and may reduce the debt‑to‑equity ratio by 0.8 percentage points.

■Project IRR: Estimated between 14%–16%.

Market Dynamics: Competitive Position in Turkey's Oncology Drug Market

■Market share gain: The agreement could lift Oncosem's share from 3.5% to 5.2% of the national oncology drug market.

■Competitive landscape: Large pharma players (e.g., Eczacıbaşı, Abdi İbrahim) have limited hospital‑based services; Oncosem's integrated offering creates a distinct advantage.

■Growth outlook: Oncology treatment volumes in Turkey are expanding at 9% annually, providing a fertile ground for additional hospital contracts.

Potential Risks and Regulatory Landscape

■Regulation: Delays in approvals from the Turkish Medicines and Medical Devices Agency (TİTCK) could affect delivery schedules.

■Pricing pressure: Public‑hospital drug price controls may cap margin expansion.

■Operational risk: Disruptions in raw‑material supply or quality‑control processes could jeopardize contract performance.

■Currency exposure: While the contract is TL‑denominated, raw‑material imports are dollar‑based, exposing costs to FX volatility.

Oncosem's strategic move not only bolsters its own P&L but also reinforces the role of domestic players in Turkey's oncology supply chain. Investors should monitor the cash‑flow uplift and margin improvements closely, while remaining cautious of regulatory and FX headwinds.